Medication info
Rosvatran 5mg (Rosuvastatin Calcium)

Rosvatran 5mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Dongkoo BioPharm Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201702134 · Approved 2017.04.26 · Insurance code 657307080

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Children's dosage
Age 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Dongkoo BioPharm Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • atherosclerosis
  • homozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
View approved original text

This medication is used as an adjunct when dietary changes and exercise are not sufficient to control primarily hypercholesterolemia and mixed dyslipidemia patients. It is particularly suitable for patients with primary hypercholesterolemia and familial hypercholesterolemia, lowering LDL-cholesterol levels and delaying the progression of atherosclerosis. It can also be safely used in pediatric and adolescent patients meeting specific criteria for familial hypercholesterolemia. It is recommended as a dietary adjunct for patients with primary dysbetalipoproteinemia. Additionally, it reduces the risk of stroke, myocardial infarction, and arterial revascularization in adult patients with elevated high-sensitivity C-reactive protein levels and risk factors for cardiovascular disease. Therefore, this medication is effectively used for various dyslipidemias and reduction of cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Children's dosage

Age 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. Patients with allergies to the ingredients of this medication, severely impaired liver function, muscle diseases, those taking certain immunosuppressants, patients with severe renal impairment, pregnant or breastfeeding women, and fertile women not using appropriate contraception should not take this medication. Moreover, patients at high risk of muscle-related conditions are prohibited from taking high doses, which includes those with moderate renal impairment, hypothyroidism, a history of hereditary muscle diseases, alcohol dependence, and concomitant use of certain drugs. This medication contains lactose, so it should not be administered to patients with lactose intolerance or related genetic disorders. During treatment with this medication, liver function abnormalities or symptoms like muscle pain and weakness should be carefully monitored, and if any adverse symptoms occur, medical personnel should be informed immediately. Patients with significant alcohol consumption or a history of liver disease should have regular liver function tests, and treatment of underlying conditions is prioritized in cases of hypothyroidism or nephrotic syndrome. This medication may interact with other drugs, so patients should inform healthcare providers of any other medications they are taking, as combining with certain medications may increase the risk of muscle diseases. Pregnant or breastfeeding women should not take this medication, and women who may become pregnant should use appropriate contraception. In case of overdose, there is no specific antidote, so appropriate treatment based on symptoms and liver and muscle enzyme tests is necessary. This medication does not significantly affect driving or operating machinery; however, caution should be taken due to possible symptoms like dizziness. During treatment, rare occurrences of interstitial lung disease, severe skin reactions, and serious liver damage may happen, so immediate discontinuation and consultation with healthcare personnel should be sought if any unusual symptoms occur. Lastly, this medication may show higher blood concentration in Asians, so dosage adjustment may be necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is best stored at a cool room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.